StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.92 | $4.35 | +10.97% | 3.0M |
| 05-12 | $4.25 | $4.16 | -2.12% | 2.8M |
| 05-13 | $4.21 | $4.66 | +10.69% | 1.6M |
| 05-14 | $4.68 | $4.74 | +1.28% | 1.2M |
| 05-15 | $4.58 | $4.80 | +4.80% | 1.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-07-30 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $44.98M | $39.39M | $151.82M | $118.38M | $83.38M |
Operating Income | Not available | $-1.80M | $-11.56M | $-10.55M | $-803.00K |
Net Income | Not available | $-2.40M | $-11.67M | $-12.95M | $-591.00K |
EPS (Diluted) | $0.01 | $-0.03 | $-0.19 | $-0.22 | $-0.06 |
Total Assets | Not available | $192.00M | $187.30M | $185.92M | $198.37M |
Total Liabilities | Not available | $91.74M | $99.59M | $103.81M | $107.21M |
Cash & Equivalents | Not available | $16.69M | $8.45M | $5.41M | $8.19M |
Free Cash Flow OCF − CapEx | Not available | $5.22M | $692.00K | $3.28M | $3.69M |
Shares Outstanding | Not available | 70.55M | 64.54M | 62.44M | 62.44M |
No sell-side coverage available for AIRS.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for AIRS.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.